Furthermore, the involvement of RORα in ILC2 development (Halim et al., 2012; Wong et al., 2012) and Type-2 immune functions (Haim-Vilmovsky,et al., 2019) may provide additional therapeutic opportunities for diseases such as asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (Gieseck et al., 2018). The gene discussed is RORA; the disease is pulmonary fibrosis.